RxDoctor Payments DataLook up a doctor →

Emily Becker, MD

Dermatology · San Antonio, TXNPI 1265619217

Payments from drug & device makers

$2,409,271in general payments, 2019–2025

Across 1,209 payments — averaging $1992.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1.1M
  • Regeneron Healthcare Solutions, Inc.$407K
  • Sanofi$369K
  • Pfizer$295K
  • Lilly USA, LLC$105K
  • Arcutis Biotherapeutics, Inc.$36K
  • plus $77K from 39 others
$5,016in research payments, 2019–2025

Across 6 payments — averaging $836.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$4K
  • Sanofi US Services Inc.$1K

What the payments were for

  • Consulting fees$101,4658%
  • Speaking & faculty fees$978,26379%
  • Travel & lodging$138,74511%
  • Food & beverage$24,2882%
  • Education$3490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,409,271 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$95,768
Medicare patients
377
Services billed
1,815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyjuvekBeremagene Geperpavec-Svdt48$1,230,528
Humira(Cf) PenAdalimumab14$180,191
OtezlaApremilast21$78,263
Dupixent PenDupilumab13$47,417
Tacrolimus23$2,846
Clobetasol Propionate38$2,016
Fluorouracil25$1,846
Pimecrolimus14$1,684
Ketoconazole96$1,662
Clindamycin Phosphate26$986
Metronidazole12$722
Triamcinolone Acetonide57$472
Fluocinonide11$353
Doxycycline Hyclate11$224
Dutasteride12$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Krystal Biotech IncVyjuvek$340$1,230,52848 claims
AmgenOtezla$1,120,239$78,26321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,098 dermatology providers in Texas.

Other dermatology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →